CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2006--Alkermes, Inc. (Nasdaq: ALKS - News) today reported its financial results for the fiscal year ended March 31, 2006. Net income on a GAAP basis for the fiscal year was $3.8 million or a basic and diluted earnings per share of $0.04, as compared to a net loss of $73.9 million or a basic and diluted loss per share of $0.82 in the prior year. The profitable year was driven by growth in each of the revenue categories, including the recognition of manufacturing and royalty revenues related to RISPERDAL® CONSTA® ((risperidone) long-acting injection), net collaborative profit related to work performed on VIVITROL(TM) (naltrexone for extended-release injectable suspension) and an increase in research and development revenues.
